Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
Nature Medicine2015Vol. 21(12), pp. 1473–1480
Citations Over TimeTop 10% of 2015 papers
Qiang Wen, Qiong Yang, Benjamin Goldenson, Sébastien Malinge, Terra L. Lasho, Rebekka K. Schneider, Lawrence J. Breyfogle, Rachael Schultz, Laure Gilles, Priya Koppikar, Omar Abdel‐Wahab, Animesh Pardanani, Brady L. Stein, Sandeep Gurbuxani, Ann Mullally, Ross L. Levine, Ayalew Tefferi, John D. Crispino
Related Papers
- → Cutaneous Myelofibrosis With JAK2 V617F Mutation: Metastasis, Not Merely Extramedullary Hematopoiesis!(2010)15 cited
- → Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis(2013)11 cited
- → Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study(2019)6 cited
- → Pierwotna mielofibroza – przegląd metod leczniczych(2014)3 cited
- → Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm(2017)2 cited